Abstract
Target-focused libraries can be rapidly selected by 2D virtual screening methods from multimillion compounds’ databases if structures of active compounds are available. In the present study, a multi-step virtual and in vitro screening cascade is used to select melanin-concentrating hormone receptor-1 antagonists. The 2D similarity search combined with physico-chemical parameter filtering is suitable for selecting candidates from multimillion compounds’ repository. The seeds of the first round of virtual screening were collected from literature commercial databases, whereas the seeds of the second round were the hits the first round of biological testing In vitro screening underlined the efficiency of our approach, as in the second screening round the hit rate (8.6 %) significantly improved compared to the first round (1.9 %), applying a strict requirement for hit selection, and also this cascade-like screening method was appropriate for selecting several compounds reaching efficacies even below 10 nM.
Notes
http://www.chemaxon.com (accessed April, 2010); InstJChem v. 5.3.1, 2010 was used for structure searching and chemical database access and management: Marvin v. 5.3.1, 2010 was used for drawing, displaying, and characterizing chemical structures and substructures: fingerprints are explained at: http://www.chemaxon.com/jchem/doc/user/fingerprint.html.
Abbreviations
- MCHR1:
-
Melanine concentrating hormone receptor-1
References
Adams SE, Glen RC (2006) Similarity Metrics and Descriptor Spaces—which Combinations to Choose. QSAR Comb Sci 26:1133–1142
Chaki S, Funakoshi T, Hirota-Okuno S, Nishiguchi M, Shimazaki T, Iijima M, Grottick AJ, Kanuma K, Omodera K, Sekiguchi Y, Okuyama S, Tran TA, Semple G, Thomsen WJ (2005) Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists. J Pharmacol Exp Ther 313:831–839
Cheon HG (2012) Antiobesity effects of melanin-concentrating hormone receptor 1 (MCH-R1) antagonists. Handb Exp Pharmacol 209:383–403
David DJ, Klemenhagen KC, Holick KA, Saxe MD, Mendez I, Santarelli L, Craig DA, Zhong H, Swanson CJ, Hegde LG, Ping XI, Dong D, Marzabadi MR, Gerald CP, Hen R (2007) Efficacy of the MCHR1 Antagonist N-[3-(1-{[4-(3,4-Difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in Mouse Models of Anxiety and Depression following Acute and Chronic Administration Is Independent of Hippocampal Neurogenesis. J Pharmacol Exp Ther 321:237–248
Decornez H, Gulyás-Forró A, Papp A, Szabó M, Sármay G, Hajdú I, Cseh S, Dormán G, Kitchen DB (2009) Design, selection, and evaluation of a general kinase-focused library. ChemMedChem 4:1273–1278
Di L, Kerns EH, Carter GT (2009) Drug-like property concepts in pharmaceutical design. Curr Pharm Des 15:2184–2194
Goodnow R, Gillespie P (2007) Hit-to-lead identification: efficient practices for drug discovery. Prog Med Chem 45:1–61
Hert J, Willett P, Wilton DJ, Acklin P, Azzaoui K, Jacoby E, Schuffenhauer A (2005) Enhancing the effectiveness of similarity-based virtual screening using nearest-neighbour information. J Med Chem 48:7049–7054
Irwin JJ, Shoichet BK (2005) ZINC–a free database of commercially available compounds for virtual screening. J Chem Inf Model 45:177–182
Johnson MA, Maggiora GM (1990) Concepts and applications of molecular similarity. Wiley, New York
Khanna V, Ranganathan S (2009) Physiochemical property space distribution among human metabolites, drugs and toxins. BMC Bioinformatics 10:S10
Kowalski TJ, Sasikumar T (2007) Melanin-concentrating hormone receptor-1 antagonists as antiobesity therapeutics current status. Biodrugs 21(5):311–321
Kym PR, Judd AS, Lynch JK, Iyengar R, Vasudevan A, Souers AJ (2007) Lead optimization strategies and tactics applied to the discovery of melanin concentrating hormone receptor 1 antagonists. Curr Top Med Chem 7(1471–1488):1471
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25
Ma XH, Zhu F, Shi Z, Liu X, Zhang JX, Yang SY, Wei YQ, Chen YZ (2012) Virtual screening methods as tools for drug lead discovery from large chemical libraries. Curr Med Chem 19(32):5562–5571
Mendez-Andino J, Wos JA (2007) MCH-R1 antagonists: what is keeping most research programs away from the clinic? Drug Discov Today 12:972–979
Morphy R (2006) The influence of target family and functional activity on the physicochemical properties. J Med Chem 49:2969–2978
Olah MM, Bologa CG, Oprea TI (2004) Strategies for compound selection. Curr Drug Discov Technol 1:211–220
Olah M, Mracec M, Ostopovici L, Rad R, Bora A, Hadaruga N, Olah I, Banda M, Simon Z, Mracec M, Oprea TI (2005) WOMBAT: World of molecular bioactivity. In: Oprea TI (ed) Chemoinformatics in drug discovery. Wiley-VCH, New York, pp 223–239
Polgár T, Keseru GM (2011) Integration of virtual and high throughput screening in lead discovery settings. Comb Chem High Throughput Screen 14:889–897
Stahura FL, Bajorath J (2004) Virtual screening methods that complement high-throughput screening. Comb Chem High Throughput Screen 7:259–269
Tovar A, Eckert H, Bajorath J (2007) Comparison of 2D fingerprint methods for multiple-template similarity searching on compound activity classes of increasing structural diversity. ChemMedChem 2:208–217
Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kenneth DK (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615–2623
Wager TT, Hou X, Verhoest PR, Villalobos A (2010) Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci 1:435–449
Willett P (2006) Similarity-based virtual screening using 2D fingerprints. Drug Discov Today 11:1046–1053
Willett P, Winterman V (1986) A comparison of some measures of intermolecular structural similarity. Quant Struct Act Rel 5:18–25
Xue L, Stahura FL, Godden JW, Bajorath J (2001) Fingerprint scaling increases the probability of identifying molecules with similar activity in virtual screening calculations. J Chem Inf Comput Sci 41:746–753
Acknowledgments
This work was partially supported by the National Development Agency (NFÜ) Grant: #KMOP-1.1.1-09/1-2009-0051).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Flachner, B., Tömöri, T., Hajdú, I. et al. Rapid in silico selection of an MCHR1 antagonists’ focused library from multi-million compounds’ repositories: biological evaluation. Med Chem Res 23, 1234–1247 (2014). https://doi.org/10.1007/s00044-013-0695-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-013-0695-0